Animal Model for Testing Market Overview
The Animal Model for Testing Market Size was estimated at 15.22 (USD Billion) in 2022. The Animal Model for Testing Market is expected to grow from 15.73 (USD Billion) in 2023 to 21.1 (USD Billion) by 2032. The Animal Model for Testing Market CAGR (growth rate) is expected to be around 3.32% during the forecast period (2024 - 2032).
Key Animal Model for Testing Market Trends Highlighted
Rapid technological advancements and the growing need for personalized medicine are driving the growth of the Animal Model for Testing market. The use of animal models in preclinical research remains crucial for understanding disease mechanisms and evaluating the safety and efficacy of new therapies.
Animal models provide researchers with a living system to investigate complex biological processes and test hypotheses that cannot be studied in vitro. The development of genetically modified animals, such as humanized mice, has further enhanced the accuracy and relevance of animal models for human diseases.
Additionally, the increasing focus on personalized medicine has created a demand for patient-derived xenografts, which allow for the study of patient-specific tumors in an animal model. These trends are expected to continue to drive the growth of the Animal Model for Testing market in the coming years.
Source Primary Research, Secondary Research, MRFR Database and Analyst Review
Animal Model for Testing Market Drivers
Increasing Prevalence of Chronic Diseases
The rising incidence of chronic diseases, such as cancer, cardiovascular diseases, and neurodegenerative disorders, has fueled the demand for animal models for testing. Animal models are essential for studying the mechanisms of disease development, evaluating the efficacy and safety of new therapies, and developing personalized medicine approaches.
The increasing prevalence of chronic diseases is expected to continue driving the growth of the Animal Model for Testing market. Growing focus on precision medicine and personalized therapies Technological advancements in animal modeling, such as genetically engineered models and patient-derived xenografts Increasing use of animal models in preclinical safety and efficacy testing of novel therapeutics.
Technological Advancements
Technological advancements have revolutionized the field of animal modeling. Genetically engineered animal models, such as knockout and transgenic mice, have enabled researchers to study the effects of specific genes on disease development. Patient-derived xenografts (PDXs) have emerged as a powerful tool for personalized medicine, allowing researchers to study the effects of therapies on tumors that are derived from individual patients.
These technological advancements have significantly enhanced the accuracy and predictive power of animal models, making them more valuable for drug discovery and development.
Development of humanized mouse models for studying human diseases Advances in imaging techniques, such as MRI and PET, for monitoring disease progression in animal models Integration of computational modeling and machine learning to improve the analysis and interpretation of animal data.
Rising Demand for Non-animal Models
Growing ethical concerns about animal testing and the need for more cost-effective and efficient models have led to the development of non-animal models. These models include cell-based assays, organ-on-a-chip systems, and computational models. While non-animal models cannot fully replace animal models, they can provide valuable complementary information and help reduce the number of animals used in research.
Increasing investment in the development and validation of non-animal models Growing adoption of non-animal models by regulatory agencies Collaboration between academia, industry, and non-profit organizations to advance the development and use of non-animal models.
Animal Model for Testing Market Segment Insights
Animal Model for Testing Market Animal Type Insights
The Animal Model for Testing Market is segmented into various animal types, including rodents (mice and rats) and non-rodents (rabbits, dogs, and primates). Each animal type offers unique advantages and disadvantages for specific research applications, leading to variations in market share and growth prospects.
Rodents, particularly mice and rats, are the most commonly used animal models in biomedical research, accounting for a significant portion of the Animal Model for Testing Market revenue. Their small size, short lifespan, and ease of genetic manipulation make them suitable for a wide range of studies, including toxicology, pharmacology, and disease modeling.
The market for rodents in animal testing is projected to reach USD 10.2 billion by 2026, exhibiting a steady growth rate due to the increasing demand for preclinical safety and efficacy testing of drugs and medical devices.
Non-rodents, such as rabbits, dogs, and primates, are also utilized in animal testing, albeit to a lesser extent compared to rodents. Rabbits are often used in dermal and ocular toxicity studies, while dogs are preferred for cardiovascular and respiratory research. Primates, such as monkeys and apes, are employed in studies requiring higher cognitive functions and complex behavioral assessments.
The market for non-rodents in animal testing is expected to expand at a moderate pace in the coming years, driven by advancements in veterinary medicine and the growing adoption of non-animal testing methods.
The choice of an Animal Model for Testing depends on several factors, including the research question, species-specific biology, ethical considerations, and regulatory requirements. Rodents offer cost-effectiveness, genetic homogeneity, and a well-established body of knowledge, making them the preferred choice for many research applications.
However, for studies involving complex physiological systems or human-specific diseases, non-rodents may be more suitable. Overall, the Animal Model for Testing Market is highly dynamic and evolving, with continuous advancements in animal welfare, ethical considerations, and alternative testing methods.
The market is expected to witness steady growth in the coming years, driven by the increasing demand for preclinical safety and efficacy testing, as well as the development of more sophisticated and human-relevant animal models.
Source Primary Research, Secondary Research, MRFR Database and Analyst Review
Animal Model for Testing Market Application Insights
The Application segment of the Animal Model for Testing Market is categorized into Drug Discovery and Development, Toxicity Testing, Safety Assessment, and Disease Modeling. Drug Discovery and Development is the largest segment and is expected to dominate the market throughout the forecast period.
This growth can be attributed to the increasing demand for animal models in the early stages of drug development to assess the efficacy and safety of new drugs. The Toxicity Testing segment is expected to grow at a significant CAGR due to the growing need for safety assessments of chemicals and consumer products.
The Safety Assessment segment is also expected to grow at a healthy rate due to the increasing regulatory requirements for product safety evaluations. The Disease Modeling segment is expected to witness moderate growth due to the growing use of animal models in understanding disease mechanisms and developing new therapies.
Animal Model for Testing Market Technology Insights
The Technology segment of the Animal Model for Testing Market is categorized into Genetically Modified Animal Models, Non-Genetically Modified Animal Models, and Patient-Derived Xenograft (PDX) Models. Genetically Modified Animal Models held the largest market share in 2023, owing to their ability to mimic human diseases more accurately.
Non-Genetically Modified Animal Models are expected to witness significant growth due to their lower cost and ease of use. Patient-derived xenograft (PDX) Models are gaining popularity as they provide a more personalized approach to drug testing.
The Animal Model for Testing Market for Genetically Modified Animal Models is projected to reach USD 6.53 Billion by 2032, exhibiting a CAGR of 4.5%. Non-Genetically Modified Animal Models market is anticipated to grow at a CAGR of 3.1%, reaching USD 5.81 Billion by 2032.
The Patient-Derived Xenograft (PDX) Model market is expected to expand at a CAGR of 4.7%, reaching USD 4.17 Billion by 2032.
Animal Model for Testing Market End-User Insights
The Animal Model for Testing Market segmentation by End-User includes Pharmaceutical Companies, Biotechnology Companies, Contract Research Organizations (CROs), and Academic Research Institutions. Pharmaceutical Companies are expected to hold the largest market share due to their extensive use of animal models in drug discovery and development.
Biotechnology Companies are also significant contributors to market growth, driven by their focus on developing innovative therapies. Contract Research Organizations (CROs) play a crucial role in providing animal testing services to pharmaceutical and biotechnology companies, contributing to market expansion.
Academic Research Institutions contribute to the market through their research on animal models for disease mechanisms and therapeutic interventions. The Animal Model for Testing Market is projected to reach USD 16.42 Billion by 2024, exhibiting a CAGR of 3.6% during the forecast period.
Animal Model for Testing Market Modality Insights
The modality segment of the Animal Model for Testing Market is classified into In Vivo, In Vitro, and Ex Vivo. In 2023, the In Vivo segment held the largest market share due to the extensive use of animal models in preclinical research and drug discovery.
In Vivo models allow researchers to study the effects of drugs and other substances on living animals, providing valuable insights into their safety and efficacy. The In Vitro segment is anticipated to exhibit a significant growth rate during the forecast period owing to the increasing adoption of cell-based assays and organ-on-a-chip technologies.
Ex-vivo models, which involve the study of tissues or organs outside of the body, are also gaining traction due to their ability to provide more controlled and reproducible results.
Animal Model for Testing Market Regional Insights
The regional markets for Animal Models for Testing are segmented into North America, Europe, APAC, South America, and MEA. North America held the largest share of the Animal Model for Testing market in 2023 and is expected to continue to dominate the market over the forecast period.
The growth of the regional market is attributed to the increasing adoption of animal models for drug discovery and safety testing, as well as the presence of major pharmaceutical and biotechnology companies in the region.
The European market for Animal Model for Testing is also expected to grow at a significant rate over the forecast period, driven by the increasing demand for personalized medicine and the growing adoption of animal models for preclinical research.
The APAC market for Animal Models for Testing is expected to witness the highest growth rate over the forecast period due to the rising investments in healthcare infrastructure and the growing demand for animal models for drug discovery and safety testing in the region. South America and MEA are expected to contribute a smaller share to the Animal Model for Testing market over the forecast period.
Source Primary Research, Secondary Research, MRFR Database and Analyst Review
Animal Model for Testing Market Key Players and Competitive Insights
Major players in the Animal Model for Testing Market are constantly striving to gain a competitive edge in the industry. These companies are investing heavily in research and development to create innovative products and technologies that cater to the evolving needs of the market.
Leading Animal Model for Testing Market players are focusing on expanding their footprint through strategic partnerships and acquisitions.
Charles River Laboratories International, Inc. is a leading provider of animal models and related services to the pharmaceutical and biotechnology industries. The company offers a wide range of animal models, including rodents, non-human primates, and dogs.
Charles River also provides a variety of services, such as animal husbandry, veterinary care, and data collection. The company has a presence with operations in North America, Europe, and Asia.
Envigo RMS, LLC is a leading provider of research models and services to the pharmaceutical and biotechnology industries. The company offers a wide range of animal models, including rodents, rabbits, and dogs. Envigo also provides a variety of services, such as animal husbandry, veterinary care, and data collection. The company has a presence with operations in North America, Europe, and Asia.
Key Companies in the Animal Model for Testing Market Include
- Horizon Discovery Group plc
- Envigo
- Transposagen Biopharmaceuticals Inc.
- The Jackson Laboratory
- Charles River Laboratories International, Inc.
- Cyagen Biosciences Inc.
- Biomodels International
- Inotiv, Inc.
- GenScript Biotech Corporation
- WuXi AppTec Co., Ltd.
- Crown Bioscience International, Inc.
- Harlan Laboratories, Inc.
- SAGE Labs
- Taconic Biosciences, Inc.
Animal Model for Testing Market Developments
A recent breakthrough in the market is the development of patient-derived xenograft (PDX) models, which are being increasingly adopted due to their ability to better mimic human tumor growth and response to therapy.
Furthermore, advancements in gene editing technologies, such as CRISPR-Cas9, are enabling the creation of more precise and sophisticated animal models for testing. These advancements are expected to drive market growth in the coming years.
Animal Model for Testing Market Segmentation Insights
Animal Model for Testing Market Animal Type Outlook
- Rodents (Mice and Rats)
- Non-Rodents (Rabbits, Dogs, and Primates)
Animal Model for Testing Market Application Outlook
- Drug Discovery and Development
- Toxicity Testing
- Safety Assessment
- Disease Modeling
Animal Model for Testing Market Technology Outlook
- Genetically Modified Animal Models
- Non-Genetically Modified Animal Models
- Patient-Derived Xenograft (PDX) Models
Animal Model for Testing Market End-User Outlook
- Pharmaceutical Companies
- Biotechnology Companies
- Contract Research Organizations (CROs)
- Academic Research Institutions
Animal Model for Testing Market Modality Outlook
Animal Model for Testing Market Regional Outlook
- North America
- Europe
- South America
- Asia Pacific
- Middle East and Africa
| Report Attribute/Metric |
Details |
| Market Size 2022 |
15.22(USD Billion) |
| Market Size 2023 |
15.73(USD Billion) |
| Market Size 2032 |
21.1(USD Billion) |
| Compound Annual Growth Rate (CAGR) |
3.32% (2024 - 2032) |
| Report Coverage |
Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| Base Year |
2023 |
| Market Forecast Period |
2024 - 2032 |
| Historical Data |
2019 - 2023 |
| Market Forecast Units |
USD Billion |
| Key Companies Profiled |
Horizon Discovery Group plc, Envigo, Transposagen Biopharmaceuticals Inc., The Jackson Laboratory, Charles River Laboratories International, Inc., Cyagen Biosciences Inc., Biomodels International, Inotiv, Inc., GenScript Biotech Corporation, WuXi AppTec Co., Ltd., Crown Bioscience International, Inc., Harlan Laboratories, Inc., SAGE Labs, Taconic Biosciences, Inc. |
| Segments Covered |
Animal Type, Application, Technology, End-User, Modality, Regional |
| Key Market Opportunities |
Increased demand for personalized medicine Growing adoption of animal models in drug discovery Advancements in gene editing technologies Expansion into emerging markets Focus on reducing animal testing |
| Key Market Dynamics |
Increasing demand for personalized medicine Technological advancements in animal modeling Growing prevalence of chronic diseases Government funding and regulatory support Rising ethical concerns regarding animal testing |
| Countries Covered |
North America, Europe, APAC, South America, MEA |
Frequently Asked Questions (FAQ) :
The Animal Model for Testing Market reached USD 15.73 billion in 2023.
The Animal Model for Testing Market is expected to grow at a CAGR of 3.32% from 2024 to 2032.
The Animal Model for Testing Market is projected to reach USD 21.1 billion in 2032.
North America is expected to hold the largest share of the Animal Model for Testing Market in 2032.
The drug discovery and development segment is expected to account for the largest share of the Animal Model for Testing Market in 2032.
Some of the key competitors in the Animal Model for Testing Market include Charles River Laboratories, Envigo, and The Jackson Laboratory.
The growth of the Animal Model for Testing Market is being driven by factors such as the increasing demand for personalized medicine, the rising prevalence of chronic diseases, and the growing need for safety and efficacy testing of new drugs and therapies.
The Animal Model for Testing Market faces challenges such as ethical concerns, regulatory issues, and the high cost of animal models.
Key trends in the Animal Model for Testing Market include the use of advanced technologies such as gene editing and artificial intelligence, and the development of alternative testing methods such as in vitro and in silico models.
The Animal Model for Testing Market plays a vital role in the healthcare industry by providing essential data for the development of new drugs and therapies.
